A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
Study sponsor: Trevi Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-05-27Actual
Enrollment · participants42Actual
Source updated2025-05-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.